Matrix metalloproteinases in isolated hypercholesterolemia

International Angiology

Volumn 24, Issue 3, 2005, Pages 300-303

  Malik, J ^a   Stulc, T ^a   Ceska, R ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cholesterol; Matrix metalloproteinases; Statins atherosclerosis

Indexed keywords

ATORVASTATIN; CHOLESTEROL; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHESIS; LIPID BLOOD LEVEL; MALE; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY; TRIACYLGLYCEROL BLOOD LEVEL; VALIDATION PROCESS;

ATHEROSCLEROSIS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PYRROLES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 27744605422     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kowalewski R, Sobolewski K, Wolanska M, Gacko M. Matrix metalloproteinases in the vein wall. Int Angiol 2004;23:164-9.
2. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995,77: 863-8.
3. Theroux P, Fuster V. Acute coronary syndromes. Circulation 1998;97:1195-206.
4. Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001;39:380-4.
5. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000;75:43-7.
6. Maxwell PR, Timms PM, Chandran S, Gordon D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med 2001;18: 777-80.
7. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85.
8. Wilson SH, Best PJ, Lerman LO, Holmes DR Jr, Richardson DM, Lerman A. Enhanced coronary vasoconstriction to oxidative stress product, 8-epi-prostaglandinF2 alpha, in experimental hypercholesterolemia. Cardiovasc Res 1999;44 601-7.
9. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res 2001;52:290-8.
10. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-9.
11. Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003;107:1479-85.
12. Kalela A, Koivu TA, Hoyhtya M, Jaakkola O, Lehtimaki T, Sillanaukee P et al. Association of serum MMP-9 with autoantibodies against oxidized LDL. Atherosclerosis 2002;160:161-5.
13. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994,94:2493-503.
14. Lijnen HR, Demeulemeester D, Van Hoef B, Collen D, Maquoi E. Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice. Thromb Haemost 2003;89:249-55.
15. Kalela A, Laaksonen R, Lehtimaki T, Koivu TA, Hoyhtya M, Janatuinen T et al. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am J Cardiol 2001;88:173-5, A6.
16. Koh KK, Ahn JY, Jin DK, Han SH, Kim HS, Choi IS et al. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. Int J Cardiol 2004;97:239-44.
17. Noji Y, Higashikata T, Inazu A, Nohara A, Ueda K, Miyamoto S et al.; Hokuriku NK-104 Study Group. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002;163:157-64.
18. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532:91-107.
19. Mohammed FF, Smookler DS, Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl 2:43-7.